Investor Presentation
9
Investor presentation First six months of 2022
Novo NordiskⓇ
Obesity care sales grew by 84% in the first half of 2022 driven by
both the US and IO
DKK
billion
NN sales and market share
within Obesity care
+63%
Global Branded AOM TRX
TRX count ('000s)
400
3%1
55%¹
84%¹
3.7
90%
84%
3.1
300
2.5
1.9
1.3
0.7
ㅎㅎ
0.1
2020
IO
INAO
200
50%
100
10%
0
2021
2022
2020
Market share (RHS)
2021
2022
Novo Nordisk
Others
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
The US
.
•
•
·
Broad commercial formulary access
of more than 80%
The 1.7mg and 2.4mg doses are
currently available in the US
Commercial production at CMO
reinitiated in Q2
Expectation to make all WegovyⓇ
doses available towards the end of
2022
International Operations
WegovyⓇ available in France with first
commercial launches expected
towards the end of 2022
Growth at CER
1Annual growth at CER. Each TRx data points represents one week of data
NAO: North America operations; IO: International operations; RHS: Right-hand side axis; Rx: Prescriptions; AOM: Anti-Obesity Medications (includes Wegovy®, SaxendaⓇ, Qsymia, Belviq and Contrave); Mg: milligram; CMO: Contract manufacturing organisation
Note: Sales growth at constant exchange rates. 63% volume growth for Global branded AOM market refers to MAT.
Source: Quarterly Company Announcement and IQVIA MAT, May 2022 (Spot rate)View entire presentation